drugset / Trial / NCT03357627
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Non-randomizedSequentialOpen-labelOther
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non-Hodgkin lymphoma (NHL) relapsed and/or refractory after at least 1 prior line of therapy and to evaluate safety and tolerability of TAK-659 and venetoclax when administered in combination.
Timeline
- Start
- 2018-02-16
- Primary completion
- 2021-08-03
- Completion
- 2021-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 200 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Subject | Venetoclax | Small molecule | 800 mg | Oral |
| Subject | Venetoclax | Small molecule | 1200 mg | Oral |
| Subject | mivavotinib | Small molecule | 40 mg | Oral |
| Subject | mivavotinib | Small molecule | 60 mg | Oral |
| Subject | mivavotinib | Small molecule | 80 mg | Oral |
| Subject | mivavotinib | Small molecule | 100 mg | Oral |